Protective effect of different doses of recombinant human interferon on central nervous system of children with severe hand-foot-mouth disease#br#
SONG Mingmei1 SUN Zhiwei1 LU Jiayun2▲
1.Department of Pediatrics, Wuxi Fifth People’s Hospital, Jiangsu Province, Wuxi 214044, China;
2.Department of Pharmacy, the 904th Hospital of Joint Logistic Support Force of Chinese People’s Liberation Army, Jiangsu Province, Wuxi 214044, China
Abstract：Objective To explore the protective effect of different doses of recombinant human interferon (hIFN) on central nervous system of children with severe hand foot mouth disease (HFMD). Methods The clinical data of 82 children with severe HFMD admitted to the 904th Hospital of the People’s Liberation Army Joint Logistic Support Force were retrospectively analyzed from March 2015 to October 2019. According to the treatment methods, they were divided into group A (conventional antiviral therapy, 20 cases), group B (2 μg/kg hIFN-α16 combined with conventional antiviral therapy, 31 cases), and group C (4 μg/kg hIFN-α16 combined with conventional antiviral therapy, 31 cases). The clinical symptoms, efficacy, immune function, and serological indexes of three groups were compared, and the incidence of adverse reactions during treatment were recorded. Results The time of rash resolution and fever resolution in group C were shorter than those in group A and B, and the time of rash resolution and fever resolution in group B were shorter than those in group A, and the differences were statistically significant (P ＜ 0.05). The total effective rate of group B and C were higher than those of group A, and the differences were statistically significant (P ＜ 0.05); there was no significant difference in total effective rate between group B and group C (P > 0.05). After treatment, CD3+ and CD4+ in three groups were higher than before treatment, group C was higher than group A and B, and group B was higher than group A, and the differences were statistically significant (P < 0.05); CD8+ in three groups were lower than before treatment, group C was lower than group A and B, and group B was lower than group A, and the differences were statistically significant (P < 0.05). After treatment, CRP, NSE, and S-100P levels in three groups were lower than those before treatment, and group C was lower than group A and B, and group B was lower than group A, and the differences were statistically significant (P < 0.05). Conclusion High-dose hIFN can significantly improve the clinical symptoms and immune function of children with severe HFMD, and has more significant protection on the central nervous system, with good safety.
宋明媚1 孙志伟1 陆佳赟2▲. 不同剂量重组人干扰素治疗对重症手足口病患儿中枢神经系统保护作用[J]. 中国医药导报, 2022, 19(3): 95-98.
SONG Mingmei1 SUN Zhiwei1 LU Jiayun2▲. Protective effect of different doses of recombinant human interferon on central nervous system of children with severe hand-foot-mouth disease#br#. 中国医药导报, 2022, 19(3): 95-98.
京公网安备 11010502046598号